Neuroscientific Biopharmaceuticals Ltd. (NSB) AI Stock Analysis

• Market Cap: AU$58.20M
• Dividend Yield: N/A
• Average Volume (3M): 520.66K
• Price to Earnings (P/E): 25.6
• Beta (1Y): 0.38
• Revenue Growth: N/A
• EPS Growth: 51.85%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 332,575,700
• 10 Day Avg. Volume: 607,941
• 30 Day Avg. Volume: 520,660
• PEG Ratio: 0.07
• Price to Book (P/B): 4.57
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 44.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: ―

Neuroscientific Biopharmaceuticals Ltd. is facing substantial financial challenges, including volatile revenue and ongoing operational inefficiencies. However, the stock shows positive technical momentum and appears undervalued, providing a mixed outlook. Investors should weigh the financial performance concerns against the potential for an undervalued investment with upside momentum.

Neuroscientific Biopharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. The company was incorporated in 2002 and is based in Cottesloe, Australia.

How the Company Makes Money

Neuroscientific Biopharmaceuticals Ltd. generates revenue primarily through the development and commercialization of its proprietary pharmaceutical products. The company's key revenue streams include licensing agreements with larger pharmaceutical companies, milestone payments, and royalties from product sales. NSB may also engage in research collaborations and partnerships with academic institutions and research organizations to advance its drug development programs. Additionally, the company might receive grants and funding from government and non-government organizations to support its research initiatives.

Neuroscientific Biopharmaceuticals Ltd. Financial Statement Overview

Summary

Neuroscientific Biopharmaceuticals Ltd. faces significant financial challenges with inconsistent revenue and profitability. While the balance sheet remains debt-free, declining cash and assets present risks. Recent positive cash flow trends provide some optimism, but the company must address operational inefficiencies to achieve sustainable growth.

Income Statement

Neuroscientific Biopharmaceuticals Ltd. has experienced significant revenue volatility with a sharp decline to zero revenue in the most recent year. The net profit margin has improved from negative to positive, driven by a one-time gain rather than operational improvements. However, consistent negative EBIT and EBITDA margins indicate ongoing operational challenges.

Balance Sheet

The company maintains a strong equity position with no debt, reflected in a high equity ratio. However, the shrinking asset base and decreasing cash reserves signal potential liquidity issues. The company has managed liabilities effectively, but sustained negative income raises concerns about future financial stability.

Cash Flow

The recent improvement in free cash flow, from negative to positive, suggests improved cash management. However, the operating cash flow remains low relative to net income gains, indicating underlying operational inefficiencies. The positive trend in free cash flow is a promising sign for potential recovery.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	2.28M	4.95M	0.00	958.77K	0.00
Gross Profit	2.19M	4.89M	-64.92K	897.36K	-56.66K
EBITDA	-1.80M	-5.96M	-10.37M	-3.12M	-2.81M
Net Income	324.21K	-1.07M	-10.44M	-3.18M	-2.87M
Balance Sheet
Total Assets	5.44M	5.29M	7.74M	14.83M	3.74M
Cash, Cash Equivalents and Short-Term Investments	4.95M	4.91M	7.22M	14.16M	3.29M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	85.68K	597.36K	2.22M	223.41K	88.53K
Stockholders Equity	5.35M	4.69M	5.52M	14.60M	3.65M
Cash Flow
Free Cash Flow	42.43K	-2.30M	-6.95M	-2.63M	-2.28M
Operating Cash Flow	44.25K	-2.30M	-6.94M	-2.60M	-2.28M
Investing Cash Flow	-1.81K	0.00	-3.87K	-29.88K	-2.38K
Financing Cash Flow	0.00	0.00	0.00	13.51M	960.80K

Neuroscientific Biopharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.21
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NSB, the sentiment is Positive. The current price of 0.21 is above the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.09, and above the 200-day MA of 0.05, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 68.39 is Neutral, neither overbought nor oversold. The STOCH value of 86.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NSB.

Neuroscientific Biopharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	€6.37B	19.85	-1.30%	2.18%	-0.14%	-46.13%
PTX	56 Neutral	AU$37.85M	―	-36.95%	―	―	11.11%
NSB	54 Neutral	AU$58.20M	25.61	26.99%	―	―	51.85%
CYYNF	―	$27.19M	―	-75.39%	―	―	―
SPHRF	―	$28.57M	―	-43.63%	―	―	―
ILA	47 Neutral	AU$40.79M	―	-143.22%	―	―	-4.06%
ADO	44 Neutral	AU$35.17M	―	-140.07%	―	62.15%	33.93%

Neuroscientific Biopharmaceuticals Ltd. Corporate Events

NeuroScientific Biopharmaceuticals Expands with New Acquisitions and Research Initiatives

NeuroScientific Biopharmaceuticals Ltd has announced preparations for two IND-enabling pre-clinical studies for EmtinB, targeting advanced glaucoma. Additionally, the company is acquiring StemSmart technology from Isopogen WA, which involves the use of mesenchymal stromal cells (MSC) derived from adult human donor bone marrow to treat various serious conditions. This acquisition positions NeuroScientific to expand its offerings in the cellular medicine market, with potential impacts on markets such as Crohn’s disease and organ transplant immuno-suppressants. The company has also secured $3.5 million in funding to support these initiatives.

Neuroscientific Biopharmaceuticals Announces Proposed Securities Issue

Neuroscientific Biopharmaceuticals Ltd announced a proposed issue of securities, including 40 million options exercisable at $0.07 and 100 million fully paid ordinary shares. This move is expected to enhance the company’s financial resources and potentially strengthen its market position, allowing it to further its research and development efforts in the biopharmaceutical field.

NeuroScientific Biopharmaceuticals Expands into Stem Cell Therapy with StemSmart Acquisition

NeuroScientific Biopharmaceuticals Ltd announced its acquisition of StemSmart, a patented stem cell technology from Isopogen WA, which is expected to enhance its portfolio and position in regenerative medicine. This acquisition includes a Special Access Program for treating fistulising Crohn’s disease, with promising early results from a Phase 2 trial. The company is also raising $3.5 million to support this expansion and has proposed new appointments to its board, signaling a strategic move to leverage the growing global recognition of stem cell therapies.

NeuroScientific Biopharmaceuticals Initiates Trading Halt for Major Announcement

NeuroScientific Biopharmaceuticals Ltd. announced a trading halt on its securities pending an announcement related to an acquisition and capital raising. This move is significant for the company as the acquisition and capital raising are considered material to its operations, potentially impacting its market positioning and stakeholder interests.

NeuroScientific Biopharmaceuticals Reports Revenue Growth and Reduced Losses

NeuroScientific Biopharmaceuticals Limited reported a 5% increase in revenues for the half-year ending December 2024, while significantly reducing its loss by 70% compared to the previous period. Despite not declaring a dividend, the company improved its net tangible assets per share from 2.44 cents to 3.23 cents, indicating a stronger financial position.